New Service Provides Accurate Results Quickly

February 15, 2011- State College, PA INDIGO Biosciences, The Nuclear Receptor Company, announces the addition of another service to its broad array of nuclear receptor screening services. The INDIGO Human AhR Screening Services package is a convenient and economical alternative to time-consuming internal assay development for researchers in drug discovery research and toxicology studies.
“We are excited to add AhR screening to our services portfolio. Although technically not a member of the Nuclear Receptor family of proteins that we specialize in, the AhR fits into a grouping of receptors that are very important in toxicology and drug metabolism”, says Dr. Jack Vanden Heuvel, CSO of INDIGO. Aryl Hydrocarbon Receptor (AhR) responds to a variety of environmentally relevant molecules and regulates expression of genes related to xenobiotic metabolism and cellular growth factors. The INDIGO Human AhR Screening Services are an attractive option for researchers conducting small-molecule screening studies of compounds that could potentially affect a number of disease states, including cancer.
The INDIGO Human AhR Screening Services can detect the activation or inhibition of activation of the receptor. Customers receive a downloadable file that includes raw and analyzed data, including dose-response plots for all test compounds and controls. Custom assays can be specially prepared for researchers who require screening against AhR from non-human species.
For more information about INDIGO Nuclear Receptor Screening Services, please contact Dr. Jack Vanden Heuvel, Chief Science Officer at INDIGO Biosciences, Inc. by calling (814) 234-1919 or by e-mailing jackvh@indigobiosciences.com. You may also visit INDIGO Biosciences, Inc. on the worldwide web at www.indigobiosciences.com.

INDIGO Biosciences, 814-234-1919, www.indigobiosciences.com
About INDIGO BIOSCIENCES
The Nuclear Receptor Company

Founded in 2005, privately-held INDIGO Biosciences, Inc. provides unique, cost-effective, reliable and user-friendly target-specific nuclear receptor assay products and contract screening services to drug developers, toxicologists and researchers within the pharmaceutical, biotechnology, chemical and nutriceutical industries.

INDIGO Biosciences developed a unique and superior processing method called CryoMite™ which provides long-term cryo-preservation of cells for shipping and storage, enabling The Company to provide its unique Nuclear Receptor Assays for third party use via overnight delivery.